Repertoire Genesis, Inc. has raised 200 million yen in series A funding round through stock allocations to the University of Tokyo Edge Capital (UTEC, CEO: Tomotaka Goji). This funding will accelerate the company's contribution to the development of new diagnostics and therapeutics through an enhancement of the TCR/BCR repertoire analysis business.